Incannex – Independent data review commences for Phase 2 trial of psilocybinassisted psychotherapy for anxiety

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL),
(‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary medicinal
cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to
announce that the PsiGAD1 clinical trial, designed to assess Incannex’s psilocybin-assisted
psychotherapy for the treatment of generalised anxiety disorder (“GAD”), has achieved its interim
milestone of 29 patients completing primary endpoint assessments. Independent analysis of the interim
study data has commenced.